



Truvada® (emtricitabine/tenofovir disoproxil fumarate) and Atripla® (efavirenz/emtricitabine/tenofovir disoproxil fumarate) – First-time generics

- On October 2, 2020, [Teva Pharmaceuticals launched AB-rated](#) generic versions of Gilead's [Truvada \(emtricitabine \[FTC\]/tenofovir disoproxil fumarate \[TDF\]\)](#) 200 mg/300 mg tablets and [Atripla \(efavirenz/FTC/TDF\)](#) tablets.
 - Truvada is also available as brand 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg tablets.
- Truvada is approved:
 - In combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV)-1 infection in adults and pediatric patients weighing at least 17 kg
 - In at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.
- Atripla is approved as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg.
- Truvada carries a boxed warning for posttreatment acute exacerbation of hepatitis B and risk of drug resistance with use of Truvada for HIV-1 PrEP in undiagnosed early HIV-1 infection.
- Atripla carries a boxed warning for posttreatment acute exacerbation of hepatitis B.
- Generic Truvada is available at a wholesale acquisition cost (WAC) of \$48.61 per tablet. Truvada has a WAC of \$61.41 per tablet.
- Generic Atripla is available at a WAC of \$78.86 per tablet. Atripla has a WAC of \$99.82 per tablet.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.